# Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis

> **NCT01359566** · PHASE3 · COMPLETED · sponsor: **XenoPort, Inc.** · enrollment: 228 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Arbaclofen placarbil 15 mg BID
- **DRUG:** Placebo
- **DRUG:** Arbaclofen placarbil 30 mg BID
- **DRUG:** Arbaclofen placarbil 45 mg BID

## Key facts

- **NCT ID:** NCT01359566
- **Lead sponsor:** XenoPort, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01359566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01359566, "Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01359566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*